MAOYAN ENT (01896) rose over 6%, gaining 6.49% to HK$8.04 by the time of writing, with a turnover of HK$41.10 million. According to industry data, the presale and midnight screening box office for the upcoming film *Demon Slayer: Kimetsu no Yaiba – The Infinity Castle Part 1 – Kyogai's Revenge* surpassed 100 million yuan and 10 million yuan, respectively, four days before its release. The film previously grossed $239 million in Japan and $133 million in North America. Additionally, *Now You See Me 3* is set for release on November 14, followed by *Zootopia 2* on November 26. Huayuan Securities noted that imported films could drive market growth, as high-quality sequels with strong past performance in China may stimulate demand. Citigroup recently initiated a 30-day positive catalyst watch on MAOYAN ENT, citing the November 14 release of *Demon Slayer*, for which the company serves as distributor. Citigroup projects the film could become China's top-grossing Japanese anime, potentially earning 1 billion yuan at the box office, contributing 108–200 million yuan in profit against its 2025 adjusted net profit forecast of 542 million yuan.